mCRPC - Results from the Triton 3 Study

preview_player
Показать описание
Alan H. Bryce, MD, presents results from the TRITON3 study comparing the efficacy of a PARP inhibitor (rucaparib) against docetaxel in mCRPC treatment.
  1. Grand Rounds in Urology
Рекомендации по теме
mCRPC - Results 0:06:24

mCRPC - Results from the Triton 3 Study

TRITON3 interim OS 0:02:59

TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPC

Dr. Hussain on 0:01:32

Dr. Hussain on Results of the PROfound Trial in mCRPC

Initial results from 0:01:07

Initial results from Phase I/II Study of ARV-766 in mCRPC

Dr. Graff on 0:01:20

Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPC

Expert Discusses Results 0:01:38

Expert Discusses Results of Analysis on Genomic Testing in mCRPC

PSMAfore Results: [177Lu]Lu-PSMA-617 0:10:20

PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC

SPLASH Trial Results 0:01:37

SPLASH Trial Results Reinforce Benefits of RLT for mCRPC After Progression on ARPI

Results of Phase 0:01:37

Results of Phase I Study Reach Primary End Point for mCRPC

Dr. Sawyers on 0:01:41

Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPC

Highlights on Lu-PSMA-617 0:03:25

Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study

PSMA PET findings 0:00:40

PSMA PET findings in 225AC-J591-treated patients with mCRPC

Dr. Oh on 0:01:19

Dr. Oh on Results From the PRINT Trial in mCRPC

Exploring the Impact 0:07:18

Exploring the Impact of PEACE III on mCRPC: Insights and Implications

PROSTATE CANCER: LIFE 0:00:55

PROSTATE CANCER: LIFE EXPECTANCY AFTER DIAGNOSIS

Phase II results 0:04:21

Phase II results of olaparib and abiraterone for mCRPC

Significance of the 0:05:16

Significance of the ERA 223 Trial in mCRPC

Phase 3 VISION 0:11:07

Phase 3 VISION Study of 177LuPSMA 617 for Metastatic Castration-Resistant Prostate Cancer

The PROpel clinical 0:01:45

The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC

Results from ACIS 0:10:00

Results from ACIS Trial of Apalutamide + Abiraterone/Prednisone in Patients with Chemo-Naive mCRPC

OS after progression 0:01:46

OS after progression on first novel hormonal therapy in mCSPC vs mCRPC

Enzalutamide treatment boosted 0:05:32

Enzalutamide treatment boosted by Radium-223 in mCRPC

Point-Counterpoint: Management of 0:20:48

Point-Counterpoint: Management of mCRPC

Evan Yu, MD, 0:02:58

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

join shbcf.ru